Skip to main content
Erschienen in: World Journal of Surgery 8/2018

16.01.2018 | Original Scientific Report

The Role of Surgery in Treating Resectable Limited Disease of Esophageal Neuroendocrine Carcinoma

verfasst von: Han-Yu Deng, Gang Li, Jun Luo, Xin-Rui Li, Guha Alai, Yi-Dan Lin

Erschienen in: World Journal of Surgery | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Esophageal neuroendocrine carcinoma (NEC) is a rare malignant tumor. The role of surgery in resectable limited disease of esophageal NEC remains unclear. How to select a specific group of limited disease of esophageal NEC who might benefit from surgery remains to be answered.

Methods

Patients undergoing esophagectomy for resectable limited disease of esophageal NEC in our department from January 2007 to June 2015 were analyzed. TNM staging system was applied to describe those patients, and according to their different long-term prognosis after surgery, those patients were subgrouped into surgery response limited disease (SRLD) group and surgery non-response limited disease (SNRLD) group. Both univariate and multivariate analyses were applied to identify potential prognostic factors.

Results

A total of 72 patients with resectable limited disease of esophageal NEC were identified for analysis. The median survival time of those patients was 21.5 months. There was no significant survival differences among stage I, stage IIA, and stage IIB patients, but all these patients had significantly longer survival than stage III patients. Therefore, stage I, stage IIA, and stage IIB patients were aggregated together as SRLD group, and stage III patients were aggregated as SNRLD group. SRLD patients obtained significantly longer survival than SNRLD patients in both univariate analysis and multivariate analysis. Moreover, adjuvant therapy could significantly benefit SRLD patients (P = 0.004) but could not benefit SNRLD patients (P = 0.136).

Conclusions

Different responses to surgery existed in resectable limited disease of esophageal NEC indicating the need of further subgrouping for those patients. The resectable limited disease of esophageal NEC could be further subgrouped into SRLD group and SNRLD group according to the TNM staging system.
Literatur
1.
Zurück zum Zitat Kloppel G (2011) Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 18(Suppl 1):S1–16CrossRefPubMed Kloppel G (2011) Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 18(Suppl 1):S1–16CrossRefPubMed
2.
Zurück zum Zitat Rindi G (2011) Wiedenmann B Neuroendocrine neoplasms of the gut and pancreas: new insights Nature reviews. Endocrinology 8:54–64PubMed Rindi G (2011) Wiedenmann B Neuroendocrine neoplasms of the gut and pancreas: new insights Nature reviews. Endocrinology 8:54–64PubMed
3.
Zurück zum Zitat Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72 Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72
4.
Zurück zum Zitat Huang Q, Wu H, Nie L et al (2013) Primary high-grade neuroendocrine carcinoma of the esophagus: a clinicopathologic and immunohistochemical study of 42 resection cases. Am J Surg Pathol 37:467–483CrossRefPubMed Huang Q, Wu H, Nie L et al (2013) Primary high-grade neuroendocrine carcinoma of the esophagus: a clinicopathologic and immunohistochemical study of 42 resection cases. Am J Surg Pathol 37:467–483CrossRefPubMed
5.
Zurück zum Zitat Nakajima Y, Zenda S, Minashi K et al (2012) Non-surgical approach to small cell carcinoma of the esophagus: does this rare disease have the same tumor behavior as SCLC? Int J Clin Oncol 17:610–615CrossRefPubMed Nakajima Y, Zenda S, Minashi K et al (2012) Non-surgical approach to small cell carcinoma of the esophagus: does this rare disease have the same tumor behavior as SCLC? Int J Clin Oncol 17:610–615CrossRefPubMed
6.
Zurück zum Zitat Diagnosis Stahel RA (1991) staging, and prognostic factors of small cell lung cancer. Curr Opin Oncol 3:306–311CrossRef Diagnosis Stahel RA (1991) staging, and prognostic factors of small cell lung cancer. Curr Opin Oncol 3:306–311CrossRef
7.
Zurück zum Zitat Wang SY, Mao WM, Du XH et al (2013) The 2002 AJCC TNM classification is a better predictor of primary small cell esophageal carcinoma outcome than the VALSG staging system. Chin J Cancer 32:342–352PubMedPubMedCentral Wang SY, Mao WM, Du XH et al (2013) The 2002 AJCC TNM classification is a better predictor of primary small cell esophageal carcinoma outcome than the VALSG staging system. Chin J Cancer 32:342–352PubMedPubMedCentral
8.
Zurück zum Zitat Micke P, Faldum A, Metz T et al (2002) Staging small cell lung cancer: veterans administration lung study group versus international association for the study of lung cancer–what limits limited disease? Lung Cancer (Amsterdam, Netherlands) 37:271–276CrossRef Micke P, Faldum A, Metz T et al (2002) Staging small cell lung cancer: veterans administration lung study group versus international association for the study of lung cancer–what limits limited disease? Lung Cancer (Amsterdam, Netherlands) 37:271–276CrossRef
9.
Zurück zum Zitat Situ D, Lin Y, Long H et al (2013) Surgical treatment for limited-stage primary small cell cancer of the esophagus. Ann Thorac Surg 95:1057–1062 Situ D, Lin Y, Long H et al (2013) Surgical treatment for limited-stage primary small cell cancer of the esophagus. Ann Thorac Surg 95:1057–1062
10.
Zurück zum Zitat Hou X, Wei JC, Wu JX et al (2013) Multidisciplinary modalities achieve encouraging long-term survival in resectable limited-disease esophageal small cell carcinoma. PloS One 8:e69259CrossRefPubMedPubMedCentral Hou X, Wei JC, Wu JX et al (2013) Multidisciplinary modalities achieve encouraging long-term survival in resectable limited-disease esophageal small cell carcinoma. PloS One 8:e69259CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Chen SB, Yang JS, Yang WP et al (2011) Treatment and prognosis of limited disease primary small cell carcinoma of esophagus. Dis Esophagus 24:114–119 Chen SB, Yang JS, Yang WP et al (2011) Treatment and prognosis of limited disease primary small cell carcinoma of esophagus. Dis Esophagus 24:114–119
12.
Zurück zum Zitat Meng MB, Zaorsky NG, Jiang C et al (2013) Radiotherapy and chemotherapy are associated with improved outcomes over surgery and chemotherapy in the management of limited-stage small cell esophageal carcinoma. Radiother Oncol 106:317–322 Meng MB, Zaorsky NG, Jiang C et al (2013) Radiotherapy and chemotherapy are associated with improved outcomes over surgery and chemotherapy in the management of limited-stage small cell esophageal carcinoma. Radiother Oncol 106:317–322
13.
Zurück zum Zitat Chen WW, Wang F, Chen S et al (2014) Detailed analysis of prognostic factors in primary esophageal small cell carcinoma. Ann Thorac Surg 97:1975–1981 Chen WW, Wang F, Chen S et al (2014) Detailed analysis of prognostic factors in primary esophageal small cell carcinoma. Ann Thorac Surg 97:1975–1981
14.
Zurück zum Zitat Jatoi A, Miller RC (2008) Should we recommend surgery to patients with limited small cell carcinoma of the esophagus? J Thorac Oncol 3:1373–1376CrossRefPubMed Jatoi A, Miller RC (2008) Should we recommend surgery to patients with limited small cell carcinoma of the esophagus? J Thorac Oncol 3:1373–1376CrossRefPubMed
15.
Zurück zum Zitat Maru DM, Khurana H, Rashid A et al (2008) Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol 32:1404–1411 Maru DM, Khurana H, Rashid A et al (2008) Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol 32:1404–1411
16.
Zurück zum Zitat Tanaka T, Matono S, Nagano T et al (2010) Surgical management for small cell carcinoma of the esophagus. Dis Esophagus 23:502–505CrossRefPubMed Tanaka T, Matono S, Nagano T et al (2010) Surgical management for small cell carcinoma of the esophagus. Dis Esophagus 23:502–505CrossRefPubMed
17.
Zurück zum Zitat Chen SB, Yang JS, Yang WP et al (2011) Treatment and prognosis of limited disease primary small cell carcinoma of esophagus. Dis Esophagus 24:114–119CrossRefPubMed Chen SB, Yang JS, Yang WP et al (2011) Treatment and prognosis of limited disease primary small cell carcinoma of esophagus. Dis Esophagus 24:114–119CrossRefPubMed
18.
Zurück zum Zitat Yau KK, Siu WT, Wong DC et al (2007) Non-operative management of small cell carcinoma of esophagus. Dis Esophagus 20:487–490CrossRefPubMed Yau KK, Siu WT, Wong DC et al (2007) Non-operative management of small cell carcinoma of esophagus. Dis Esophagus 20:487–490CrossRefPubMed
19.
Zurück zum Zitat Lu XJ, Luo JD, Ling Y et al (2013) Management of small cell carcinoma of esophagus in China. J Gastrointest Surg 17:1181–1187 Lu XJ, Luo JD, Ling Y et al (2013) Management of small cell carcinoma of esophagus in China. J Gastrointest Surg 17:1181–1187
20.
Zurück zum Zitat Deng HY, Ni PZ, Wang YC et al (2016) Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection. J Thorac Dis 8:1250–1256CrossRefPubMedPubMedCentral Deng HY, Ni PZ, Wang YC et al (2016) Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection. J Thorac Dis 8:1250–1256CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Lv J, Liang J, Wang J et al (2008) Primary small cell carcinoma of the esophagus. J Thorac Oncol 3:1460–1465 Lv J, Liang J, Wang J et al (2008) Primary small cell carcinoma of the esophagus. J Thorac Oncol 3:1460–1465
22.
Zurück zum Zitat de Hoyos A, DeCamp MM (2014) Surgery for small cell lung cancer. Thorac Surg Clin 24:399–409 de Hoyos A, DeCamp MM (2014) Surgery for small cell lung cancer. Thorac Surg Clin 24:399–409
23.
Zurück zum Zitat Hudson E, Powell J, Mukherjee S et al (2007) Small cell oesophageal carcinoma: an institutional experience and review of the literature. Br J Cancer 96:708–711 Hudson E, Powell J, Mukherjee S et al (2007) Small cell oesophageal carcinoma: an institutional experience and review of the literature. Br J Cancer 96:708–711
24.
Zurück zum Zitat Zou B, Li T, Zhou Q et al (2016) Adjuvant therapeutic modalities in primary small cell carcinoma of esophagus patients: a retrospective cohort study of multicenter clinical outcomes. Medicine 95:e3507CrossRefPubMedPubMedCentral Zou B, Li T, Zhou Q et al (2016) Adjuvant therapeutic modalities in primary small cell carcinoma of esophagus patients: a retrospective cohort study of multicenter clinical outcomes. Medicine 95:e3507CrossRefPubMedPubMedCentral
Metadaten
Titel
The Role of Surgery in Treating Resectable Limited Disease of Esophageal Neuroendocrine Carcinoma
verfasst von
Han-Yu Deng
Gang Li
Jun Luo
Xin-Rui Li
Guha Alai
Yi-Dan Lin
Publikationsdatum
16.01.2018
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 8/2018
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-018-4475-3

Weitere Artikel der Ausgabe 8/2018

World Journal of Surgery 8/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.